Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis.
OBJECTIVE
To determine the efficacy of sustained topical therapy with dorzolamide hydrochloride, 2%, on visual acuity and cystic macular lesions in patients with juvenile X-linked retinoschisis (XLRS).


METHODS
Retrospective analysis.


METHODS
University hospital, tertiary care referral center.


METHODS
Twenty-nine eyes of 15 patients with XLRS receiving treatment with the topical dorzolamide formulation for 4 to 41 months were enrolled.


METHODS
Changes in visual acuity, cystic macular lesions, and central foveal zone thickness on optical coherence tomography during follow-up for the duration of treatment.


RESULTS
Among the 15 patients with XLRS, 20 eyes (69%) of 11 patients showed a positive response to treatment. Five of the 20 eyes (25%) in 3 of the 11 patients showed an initial response and a subsequent rebound of macular cysts. In 4 eyes (14%) of 3 patients, there was no response to treatment, but the macular cysts did not worsen compared with the baseline level. In 5 additional eyes (17%) of 4 patients, there was no response to treatment, and the macular cysts worsened when compared with the baseline level. Sixteen eyes (55%) of 12 patients had improvement in best-corrected visual acuity by at least 7 letters in at least 1 eye at the most recent follow-up visit. Seventeen eyes (59%) of 10 patients showed a reduction in the central foveal zone thickness in at least 1 eye when compared with the pretreatment level.


CONCLUSIONS
Patients with XLRS have the potential to experience a beneficial effect from sustained treatment with dorzolamide, 2%.
Genead
Mohamed A
MA
Department of Ophthalmology and Visual Sciences, Eye and Ear Infirmary, University of Illinois at Chicago, IL, USA.
Fishman
Gerald A
GA
Walia
Saloni
S
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage*; D005136:Eye Proteins / Q000235:genetics; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D041441:Retinoschisis / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D012189:Retrospective Studies; D013449:Sulfonamides / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
D002257:Carbonic Anhydrase Inhibitors; D005136:Eye Proteins; D009883:Ophthalmic Solutions; C108726:RS1 protein, human; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide